Bernardo Llovera to the part of Seat of the Board, changing Hank Vander Laan, who continues to be on the board.. BIOREM announces proposed personal keeping $1.5 million BIOREM Inc. is very happy to announce a proposed personal placement of up to at least one 1,500 Devices at a cost per Unit of $1,000 for gross proceeds as high as $1.5 million.00 percent convertible extendible secured subordinated debentures with a maturity day 24 months from the time of issuance and 4,545 common share buy warrants .11 per Common Share.67 percent of the then outstanding principal amount of Debentures.11 per talk about for an interval of two years from issuance. BIOREM intends to utilize the arises from the private positioning for functioning capital and general corporate reasons.Pre-clinical studies have verified the efficacy of BiondVax’s vaccine. Furthermore, BiondVax has concluded two Stage I/II clinical trials, where the vaccine demonstrated both basic safety and immunogenicity in both youthful and older adults. The business is currently getting ready to commence its 1st Phase II medical trial, expected to be finished by mid-2011. ‘BiondVax is honoured to get this prestigious award from Frost & Sullivan,’ commented Dr. Ron Babecoff, CEO of BiondVax. ‘We think that our common influenza vaccine is actually innovative, and gets the potential to significantly change how we guard ourselves against the flu, not merely from season to time of year, but from any possibly virulent and dangerous pandemic flu strains also. ‘ Each full yr, Frost & Sullivan presents this award to a organization that has developed a forward thinking element in something by leveraging cutting-edge technology.